{"name":"Bioprojet","slug":"bioprojet","ticker":"","exchange":"","domain":"","description":"","hq":"Paris","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"BF2.649","genericName":"BF2.649","slug":"bf2-649","indication":"Narcolepsy type 1","status":"phase_3"},{"name":"BF2.649 (pitolisant)","genericName":"BF2.649 (pitolisant)","slug":"bf2-649-pitolisant","indication":"Narcolepsy type 1 and type 2","status":"phase_3"},{"name":"BP1.3656 high dose","genericName":"BP1.3656 high dose","slug":"bp1-3656-high-dose","indication":"Other","status":"phase_2"},{"name":"BP1.4979","genericName":"BP1.4979","slug":"bp1-4979","indication":"Other","status":"phase_2"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"BP1.4979 active drug","genericName":"BP1.4979 active drug","slug":"bp1-4979-active-drug","indication":"Hypertension","status":"phase_2"},{"name":"BP1.3656 intermediate dose","genericName":"BP1.3656 intermediate dose","slug":"bp1-3656-intermediate-dose","indication":"Hypertension","status":"phase_2"},{"name":"BP1.3656 low dose","genericName":"BP1.3656 low dose","slug":"bp1-3656-low-dose","indication":"Hypertension","status":"phase_2"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"BF2.649 add on Modafinil","genericName":"BF2.649 add on Modafinil","slug":"bf2-649-add-on-modafinil","indication":"Excessive daytime sleepiness in narcolepsy (as add-on to modafinil)","status":"phase_3"}]}],"pipeline":[{"name":"BF2.649","genericName":"BF2.649","slug":"bf2-649","phase":"phase_3","mechanism":"BF2.649 is a histamine H3 receptor antagonist that increases histamine signaling in the brain to promote wakefulness and cognitive function.","indications":["Narcolepsy type 1","Excessive daytime sleepiness"],"catalyst":""},{"name":"BP1.4979 active drug","genericName":"BP1.4979 active drug","slug":"bp1-4979-active-drug","phase":"phase_2","mechanism":"BP1.4979 is a small molecule drug that targets the renin-angiotensin system.","indications":["Hypertension"],"catalyst":""},{"name":"BF2.649 (pitolisant)","genericName":"BF2.649 (pitolisant)","slug":"bf2-649-pitolisant","phase":"phase_3","mechanism":"Pitolisant is a selective histamine H3 receptor antagonist that increases histamine release in the brain to promote wakefulness.","indications":["Narcolepsy type 1 and type 2","Idiopathic hypersomnia"],"catalyst":""},{"name":"BF2.649 add on Modafinil","genericName":"BF2.649 add on Modafinil","slug":"bf2-649-add-on-modafinil","phase":"phase_3","mechanism":"BF2.649 is a histamine H3 receptor antagonist that enhances wakefulness and cognitive function when combined with modafinil's dopamine/norepinephrine reuptake inhibition.","indications":["Excessive daytime sleepiness in narcolepsy (as add-on to modafinil)","Cognitive impairment and fatigue in neurological conditions"],"catalyst":""},{"name":"BP1.3656 high dose","genericName":"BP1.3656 high dose","slug":"bp1-3656-high-dose","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BP1.3656 intermediate dose","genericName":"BP1.3656 intermediate dose","slug":"bp1-3656-intermediate-dose","phase":"phase_2","mechanism":"BP1.3656 intermediate dose is a medication that helps to lower blood pressure by affecting the body's ability to regulate blood vessel constriction.","indications":["Hypertension"],"catalyst":""},{"name":"BP1.3656 low dose","genericName":"BP1.3656 low dose","slug":"bp1-3656-low-dose","phase":"phase_2","mechanism":"BP1.3656 low dose is a medication that lowers blood pressure by acting on the renin-angiotensin system.","indications":["Hypertension"],"catalyst":""},{"name":"BP1.4979","genericName":"BP1.4979","slug":"bp1-4979","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9WdlQ5cnF0QUg4aUE3a2FxT1NYVkNsa1JRNEE3UV9VR2UybGprVjhLWV9vaE5ZM1JMWnFWSm90RDdJZXUyVnNDNm5kNmJEUWFyMVQwd0FvYk5LenE1UUNZ?oc=5","date":"2026-03-16","type":"pipeline","source":"Nature","summary":"Correction: Histamine H3 Receptor as a target for alcohol use disorder: challenging the predictability of animal models for clinical translation in drug development - Nature","headline":"Correction: Histamine H3 Receptor as a target for alcohol use disorder: challenging the predictability of animal models ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxPcXlvd21oOFVsbzRCQi10M21uX2FUNEZlWjZYZVVfZXdoZ2JlR290UUtTSk52bHIzVkVtQXJUWW9oc0F1QVN4dkVKcDFjQW1fbncxajVBRTVZSkVQNmlpUWp5UHcxNUJZYzlDTWhiblZnS01Vek4xYlAtZ0s3RHhBMlBqS184YUZtZlRIMUMzMG50S05ZajBVN0JLTjJZMWd0WlVVMzVrb09aQnU2Z01xZWNJUnM2NnNoT0xMT1Q0RzY2WXJWNXBhU3JwOA?oc=5","date":"2025-11-19","type":"trial","source":"Sleep Review","summary":"Harmony Advances First Human Study of Orexin 2 Agonist - Sleep Review","headline":"Harmony Advances First Human Study of Orexin 2 Agonist","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNRlAxalkyMk5iWGxuYWltSkV1NTBTY3BzSDB2WWJLMW41MXhlaUZxUURaOVVyNXNOakFGUEtUMjNraFJBWnoxbGp0NFpGNnZKWkJEb2twb0lUN0cza29hc0FYQUpHc0xnYjFMT2oxaDRMb2ZXbHZwamUxdURhQ2IwWDBDbk1MaFRMemJoaGVnRmtWT1ZnUnI0cXVFLS15Yms?oc=5","date":"2025-09-17","type":"pipeline","source":"BioWorld News","summary":"BP1.15205 promotes wakefulness in monkeys, ready for clinic - BioWorld News","headline":"BP1.15205 promotes wakefulness in monkeys, ready for clinic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQUUZleGZNNTZzcEFKeTc2Q1FjMmI4UkpnT09ueHhSem8xbzNOaktiYllWOWFUZEpsZnN4MlJMWlNXbVRlWjY5U0JSRFdDVXpucWhUbzhmQkpkVndHSzlORlhucTlpSnVCd3ExYkw0eDF4OTByOWtkcU9aOGZvZktqenBxdV8wa3c?oc=5","date":"2025-03-26","type":"pipeline","source":"Future Market Insights","summary":"Excessive Daytime Sleepiness Market Size, Sales & Share 2035 - Future Market Insights","headline":"Excessive Daytime Sleepiness Market Size, Sales & Share 2035","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNMXhtNThhakZCMHVxS3ZCbjIyazlMakdEZjlCbnJjeGQ1Ym12QmxudGNReGpLejRDX0ozWXp2S3lQZUpOS3NqVWpvV3B4UDBVOEV2SUdzN1dqRS1aUWVSUko5YzhRR292eWgtU1FGOUZOX05Nb0RBRlFFQl9Yd25wUjFSRUc5YzJJTS1mTG1HbU9XcHJOZ2FpLUczSC16ZE8yUTJPOGtLLTlSTHJ4WnIwQVBzT29vay1nTmtJNzRVTVU?oc=5","date":"2025-03-24","type":"pipeline","source":"Fierce Pharma","summary":"Eyeing blockbuster sales, Harmony names Takeda veteran Adam Zaeske chief commercial officer - Fierce Pharma","headline":"Eyeing blockbuster sales, Harmony names Takeda veteran Adam Zaeske chief commercial officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5sZDdaMjBnTXI2UERoVVZsVTN0eGV3bWs1MmlHTkJwSTlmRVZTUVg2REt3eldnVkYybFBPZ1NjN2lGTlhvdmh6Rlh2d0RLVUdDMnBITlQ0TWltTkhzT2Q4UjduWmR1bzhlaUtRUnZR0gFyQVVfeXFMTk9kSnNmUzhiZzlmZktUZUp3NnQzVkRVdHd2ejV3S1hCT3BqekczcWxGejJ0QmlFOWNWZzBYRDhWUUlNYWxPZUwwb2I0S3E2ZFI4bzZJOWpmVWZTaGFiOUt3bzlZTjROX0JkRHp3a3F6eWhB?oc=5","date":"2025-03-14","type":"pipeline","source":"koreabiomed.com","summary":"Narcolepsy patients face drug shortages, rising costs as key medications are discontinued in Korea - koreabiomed.com","headline":"Narcolepsy patients face drug shortages, rising costs as key medications are discontinued in Korea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxOcUZNZGRFOHdXR0c2UFZVeG54RFF0LXIzNjNJd2JjM0t5VmNmeDd3aHZ2MEFUSTFXMXA0bXBYa3lWX3ZrblY5WjgyalVVdU12clR1aWxRZmNxY3BVM0EtSzNmcF9fOTJMY20taVl0Ym9BWUxQNDV2YWhta0tJT3pmZ0ZrS3ZncW9pOE5vSE1oQ2NnTXVidFFrS2tSSW1WOUFFemY2TWd3NFNyc2JqVVY1WUFiNEtzRzZfbzF1NFBlSzRPemRGYkxZN2lBeGpWTW91?oc=5","date":"2024-08-13","type":"trial","source":"European Medical Journal","summary":"Updated Insomnia Guidelines and Latest Real-World Evidence Data on Daridorexant - European Medical Journal","headline":"Updated Insomnia Guidelines and Latest Real-World Evidence Data on Daridorexant","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQZFROa3BRLWhpZ05rLWhYeGdBeUNyMVVyWmVpd2k1Wk5URURZN1N3M2RaaGdhbmg5ZXZ3d0ZYVW8wWGFTX0p1d1pFQXk5NU4wVktLb0dRcGNzc0VzeUNRQjNDMzdhMnlfNWJxaVk3S2hVemo1Z0hHNEJEZnFsRnZaYnpRWlhqakxJaDB6WjhxNzVidXAtYXNzcHBpMW5FM1ZZa2MtZzF0NURORWtVRmpRRTVNQlVtamxMRFJHcHVrb1FBaktRd0E?oc=5","date":"2023-03-28","type":"pipeline","source":"Fierce Pharma","summary":"After Twist and Ginkgo campaigns, Scorpion Capital aims stinger at Harmony Biosciences - Fierce Pharma","headline":"After Twist and Ginkgo campaigns, Scorpion Capital aims stinger at Harmony Biosciences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNRjlVLW0tYVp1RUpyaWpmdkRJVTVQbUZfbVlJajdqY0JEZlgzbExqd2E0ODV6QkNDanZyVmp1d3VSaVd4U05oRHV0ZXEzRWFmVjBJWjJaNEZ3QUlmeEZCenNiUENiMHBCMS1YRDljVm5fMGRzSll5Q2JuX1BNeVdDMVIzdF8zeC0taGhqSWk2LU5iZ2toVnRPTEY3emdXTjVzLTlvdmUtaU9PRFBZYWgxWmRpNkxDb1Vpa21tVE5PZw?oc=5","date":"2021-09-03","type":"pipeline","source":"PR Newswire","summary":"Bioprojet: European Marketing Authorisation for OZAWADE™ - PR Newswire","headline":"Bioprojet: European Marketing Authorisation for OZAWADE™","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNSndMVlAwQ3VNODFYTW1oY2FtTzJLaGNfeXM1UXJXU0dyNlRJbGdRazFUblBncjZGbnJKMkdYZDBWX1FKSEJNbDZTYmh4VUdZYUt6aWJlQ0Y3UGw0UlRMTXRaNi1vZXlwVjZtNmx0N2w3NUV6ZTNtbUNPSXE3b2swb0s1MF94Z21FakJSM1NFMXo3V0U2QUFVdHhfTWFUSV9RUkQw?oc=5","date":"2019-08-15","type":"regulatory","source":"Fierce Pharma","summary":"Harmony Biosciences scores first approval in narcolepsy med Wakix - Fierce Pharma","headline":"Harmony Biosciences scores first approval in narcolepsy med Wakix","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxOTmRoaUFXN1VHWWtvTkNtTzluSWp1cG54eWNZZzZGQVFONWFpSG5IdXA1eHp0R1V1UV9IWVBQYUdBcm9Xel8xOGgwSzk0RWh4WHdyVDdqWUdBbG41aWFfRS1rMl92TUsySWVjTDg1cDVicVVkNkhFNGlrOWJFQkp6Z2RmLTJIa1hsLTZPRWpyU2VpZGRkWjNEdVNoRG05Sm5FR1pwZGJ0MktTakNnZXRvUzdvV2dfT0dNTm5HMkhpeEJFek13aC1lQUhIckhiLTdacDZzdHR3bVRSMkI4bjJfT1E3WUtfVUM3OW9IOU1IRkh4NWZF?oc=5","date":"2017-10-06","type":"deal","source":"PR Newswire","summary":"Harmony Biosciences Acquires US Rights to Pitolisant From Bioprojet; Raises $270 Million in Equity Financing - PR Newswire","headline":"Harmony Biosciences Acquires US Rights to Pitolisant From Bioprojet; Raises $270 Million in Equity Financing","sentiment":"neutral"}],"patents":[],"drugCount":8,"phaseCounts":{"phase_3":3,"phase_2":5},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}